Skip to content
Poster

Nintedanib does not improve lung function and fibrosis in a spirometry-confirmed and bleomycin-induced mouse model of IPF

Background & Aim:

Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal interstitial lung disease, characterized by progressive lung fibrosis and declining pulmonary function. Nintedanib is currently one of only two drugs that are clinically approved for treating IPF patients.

The present study aimed to characterize Nintedanib in a bleomycin-induced (BLEO) and spirometry-confirmed mouse model of IPF.

Subjects
BLEO-IPF mouseMouseBody weightBioinformaticsIdiopathic pulmonary fibrosisHistopathology scoreImage analysisImmunohistochemistry (IHC)Lung functional testLung biochemistryNext-generation sequencingTGF-betaSpirometryWhole-body plethysmographyNintedanib

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top